PT - JOURNAL ARTICLE AU - Wakeling, Matthew N. AU - Owens, Nick D. L. AU - Hopkinson, Jessica R. AU - Johnson, Matthew B. AU - Houghton, Jayne A.L. AU - Dastamani, Antonia AU - Flaxman, Christine S. AU - Wyatt, Rebecca C. AU - Hewat, Thomas I. AU - Hopkins, Jasmin J. AU - Laver, Thomas W. AU - Van Heugten, Rachel AU - Weedon, Michael N. AU - De Franco, Elisa AU - Patel, Kashyap A. AU - Ellard, Sian AU - Morgan, Noel G. AU - Cheesman, Edmund AU - Banerjee, Indraneel AU - Hattersley, Andrew T. AU - Dunne, Mark J. AU - International Congenital Hyperinsulinism Consortium AU - Richardson, Sarah J. AU - Flanagan, Sarah E. TI - A novel disease mechanism leading to the expression of a disallowed gene in the pancreatic beta-cell identified by non-coding, regulatory mutations controlling <em>HK1</em> AID - 10.1101/2021.12.03.21267240 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.03.21267240 4099 - http://medrxiv.org/content/early/2021/12/05/2021.12.03.21267240.short 4100 - http://medrxiv.org/content/early/2021/12/05/2021.12.03.21267240.full AB - Gene expression is tightly regulated with many genes exhibiting cell-specific silencing when their protein product would disrupt normal cellular function. This silencing is largely controlled by non-coding elements and their disruption might cause human disease. We performed gene-agnostic screening of the non-coding regions to discover new molecular causes of congenital hyperinsulinism. This identified 14 non-coding de novo mutations affecting a 42bp conserved region encompassed by a regulatory element in intron 2 of Hexokinase 1 (HK1), a pancreatic beta-cell disallowed gene. We demonstrated that these mutations resulted in expression of HK1 in the pancreatic beta-cells causing inappropriate insulin secretion and congenital hyperinsulinism. These mutations identify a regulatory region critical for cell-specific silencing. Importantly, this has revealed a new disease mechanism for non-coding mutations that cause inappropriate expression of a disallowed gene.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSEF has a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (105636/Z/14/Z). MaNW and MBJ are the recipients of an Independent Fellowship and TWL and NO a Lectureship from the Exeter Diabetes Centre of Excellence funded by Research Englands Expanding Excellence in England (E3) fund. EDF is the recipient of a Diabetes UK RD Lawrence fellowship (19/0005971). KAP has a Career Development fellowship funded by the Wellcome Trust (219606/Z/19/Z). IB and MJD were supported by the Northern Congenital Hyperinsulinism (NORCHI) charitable fund, by the Manchester Academic Health Sciences Centre and by The University of Manchester MRC Confidence in Concept (CiC) Award (MC-PC-18056). SJR and NGM are grateful to JDRF for funding (2-SRA-2018-474-S-B). Ivo Barić is member of the European Reference Network for Rare Hereditary Metabolic Disorders (MetabERN), Project ID No 739543.This research was performed with the support of the Network for Pancreatic Organ donors with Diabetes (nPOD; RRID: SCR-014641), a collaborative type 1 diabetes research project supported by JDRF (nPOD: 5-SRA-2018-557-Q-R) and The Leona M. &amp; Harry B. Helmsley Charitable Trust (Grant#2018PG-T1D053, G-2108-04793). The content and views expressed are the responsibility of the authors and do not necessarily reflect the official view of nPOD. Organ Procurement Organizations (OPO) partnering with nPOD to provide research resources are listed at http://www.jdrfnpod.org/for-partners/npod-partners/. This research has been conducted using the UK Biobank Resource. This work was carried out under UK Biobank project number 9055 and 9072. Targeted next-generation sequencing to exclude known disease-causing mutations was funded by Congenital Hyperinsulinism International (a 501(c)3 organisation) for 20 individuals within the discovery cohort.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical approval for the patient DNA analysis in this study was part of the Genetic Beta Cell Research Bank based in Exeter this was approved by Wales Research Ethics Committee 5 on 20/05/13 (REC ref 12/WA/0225) and renewed on 26/10/2017 (REC ref 17/WA/0327).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.